Chimeric Antigen Receptor (CAR) T-cell Persistence at Month 3 (M3) Predicts Clinical Outcomes in Adult Patients (pts) with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (R/R B-ALL) Treated with Obecabtagene autoleucel (obe-cel)

Transplantation and Cellular Therapy 2026

View at publisher
Authors: Claire Roddie, Jae H Park, Eleni Tholouli, Karamjeet Sandhu, Paul J. Shaughnessy, Pere Barba, Manuel Guerreiro, Deborah Yallop, Aaron C. Logan, Mehrdad Abedi, Pierre Lao‐Sirieix, Ping Wang
+5 more Wolfram Brugger, Bijal D Shah, Michael R Bishop, Daniel J. DeAngelo, Elias Joseph Jabbour
DOI: 10.1016/j.jtct.2025.12.050
Cited by: 0

Fields of Study & Subjects

CAR-T cell therapy research Acute Lymphoblastic Leukemia research Immunotherapy and Immune Responses

Publication details

Journal / source
Transplantation and Cellular Therapy
Volume
32
Issue
2
Pages
S30–S31
Publication date
1 February 2026
Language
EN